Recro Pharma Inc. on Tuesday said it is seeking to raise $15 million in an public stock offering. The Malvern, Pennsylvania, specialty pharmaceutical company is selling just under 2 million shares of its common stock at $7.50 per share. Recro Pharma (Nasdaq: REPH) intends to use the bulk of the the net proceeds from the offering to fund ongoing late-stage testing of its injectable meloxicam pain relief medicine.